On April 9, 2023, gaoxinpu, the director of the medical administration of Hainan Provincial Health Commission, luohongqiang, the deputy director of Hainan Provincial Health Commission / Lecheng medical and drug administration, xucaiyun, a cadre of the medical administration of Hainan Provincial Health Commission, tanghongming, the deputy director of the Industrial Investment Promotion Department of Hainan Boao Lecheng administration, he Chang in charge, Yan Lin, the executive director of Hainan Boao Lecheng Development Research Institute Wangxinping, an expert member of the legal policy center of Hainan Boao Lecheng Development Research Institute, and a legislative research team composed of research commissioners linhongming and sheneucheng came to Chengdu Shilian Health Biotechnology Co., Ltd. to hold a research meeting on the Legislative Research on the promotion regulations of biomedical new technologies in the international medical tourism pilot area of Hainan free trade port Boao Lecheng. Caoli, a department level researcher of the science and Education Department of the Sichuan Provincial Health Commission, wuyusong, deputy director of the science and Education Department of the Chengdu Municipal Health Commission, wuchengyun, a researcher of the Sichuan food and drug examination and evaluation and safety monitoring center, tianweidong, a professor at West China Stomatological Hospital of Sichuan University, ran Xingwu, Wei Quan, a professor at West China Hospital of Sichuan University, Suxu, a professor at West China Second Hospital of Sichuan University, Xiang hangchen, Deputy Secretary General of the Sichuan stem cell technology and cell therapy association And leaders of Chengdu Kangjing Biotechnology Co., Ltd., Chengdu yousanuo Biotechnology Co., Ltd. and Chengdu Shilian Health Biotechnology Co., Ltd. participated in the meeting. Later, accompanied by Professor tianweidong, the founder and chief scientist of WorldUnion health group, the participants jointly visited the company's cell production and preparation platform, quality detection and evaluation center and Sichuan cell bank.
Leaders of the health care Commission / professors from West China / leaders of industry associations / representatives of enterprises express their views from different perspectives
Hainan Province has come to Sichuan to carry out legislative research activities in response to the regulations on the promotion of biomedical new technologies in the international medical tourism pilot area of Boao Lecheng, a free trade port in Hainan (proposed name), in order to actively respond to the relevant requirements of the national development and Reform Commission on the implementation plan for supporting the construction of the international medical tourism pilot area of Boao Lecheng, and promote the further development of biomedical new technology industry in the pilot area of Lecheng, Realize the overall acceleration of the development of new biomedical technologies in Lecheng pilot area. The research work meeting focused on the development of new biomedical technologies, regulatory status, transformation and application, policy optimization suggestions and other issues, discussed how to achieve benign regulation through Lecheng biomedical new technology related legislation, and made suggestions and suggestions for promoting the high-quality development of the industry.
At the meeting, relevant leaders of Sichuan Provincial Health Commission and Chengdu Municipal Health Commission introduced the general situation of Sichuan Province in stem cell clinical research filing and regenerative medicine in clinical application, as well as Chengdu's relevant support policies for stem cell clinical research. Professor tianweidong from West China stomatological hospital expressed his views on the industrial development direction of the park and the technical path of regulation legislation, shared the advanced cases of successful legislation in the world, and put forward suggestions on the scope and path of new biomedical technology legislation. Three professors from West China Hospital and West China Second Hospital expressed their respective views from the perspective of clinical research and application. The Deputy Secretary General of Sichuan stem cell technology and cell therapy association put forward targeted suggestions in combination with cell testing, ethical review, standard formulation, academic exchanges, clinical research and other aspects.
Sichuan Provincial participating leaders and experts attended the meeting
As the enterprise representative of this legislative research, tangyingfeng, the deputy general manager of WorldUnion health group, introduced the company's development and development plan at the meeting. Founded by the government, World Health Group has built a four in one development model of "medicine, education, research and production" relying on the century old super first-class medical clinical strength in West China and the national scientific research platform. The expert team of Professor Tian Weidong, the chief scientist of the national 973 project, has focused on stem cell drug research and development and clinical transformation application of cell therapy for more than 20 years, adhering to the core concept of "professionalism, standards and norms", Build an open cell drug incubation platform that meets the highest level of cell GMP process standards in China. Sichuan Cell Bank Co., Ltd. is a clinical grade international cell resource bank under the world union health group that focuses on cell storage, conforms to international standards, and is open and shared. It has obtained the national qualification for human genetic resources preservation in China issued by the Ministry of science and technology, and is the first third-party biological sample bank with this qualification in the whole southwest region. This time, Hainan Boao Lecheng plans to legislate on new biomedical technologies. From the perspective of enterprises, World Health Group expects to expand more research and transformation projects in Lecheng pilot area.
From the above point of view, the relevant leaders of Hainan Provincial Health Commission and the relevant department leaders of Hainan Boao music city carried out a discussion in combination with the relevant national regulations and the current situation of Hainan Boao. They said that West China Music City must introduce domestic and foreign advanced technology, refer to and study the relevant laws and regulations of regenerative medicine in Japan, Taiwan and other places, and grasp the key points of legislation first, while doing and improving. We hope to continue to cooperate with West China Hospital and other research institutions, and finally promote the introduction of new biomedical technology promotion regulations.
Hainan provincial research group attended the meeting
Research on the legislation of new biomedical technology promotion regulations the first stop in China came to WorldUnion health
Chengdu Shilian Health Biotechnology Co., Ltd. was jointly founded by West China Hospital, West China stomatological hospital, and West China second hospital. It has now established the Sichuan provincial regional cell preparation center, the third-party cell quality testing center, and the first third-party biological sample bank (Sichuan cell bank) in Southwest China to obtain the human genetic resources collection in China, which is the phase I goal of "one library and two centers". The world union health group is a representative enterprise in the cell industry in Sichuan Province. That is why the first stop in China for the legislative research and Research on the promotion regulations of biomedical new technologies in the international medical tourism pilot area of Boao Lecheng, a free trade port in Hainan, came to Chengdu and the World Union health group.
After the survey work meeting, the leaders of both sides and all participants visited and exchanged views on the Sichuan cell bank, cell preparation platform and cell quality detection platform accompanied by Professor Tian Weidong, founder and chief scientist of World Union health group.
